Technology | Contrast Media | February 02, 2017

Lantheus Medical Imaging Announces FDA Approval of Definity Label Update

Label revision removes cardiac shunt contraindication

Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication

February 2, 2017 — Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity Vial for (Perflutren Lipid Microsphere) Injectable Suspension. The update removes the contraindication statement related to use in patients with a known or suspected cardiac shunt from the U.S. Prescribing Information.

Definity is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

A cardiac shunt is a pattern of blood flow in the heart that deviates from the normal path of the circulatory system, which may present in 10 to 35 percent of patients. These patients were previously excluded from receiving a valuable echo contrast study of the left ventricle. The FDA’s decision to remove the contraindication concerning known or suspected cardiac shunts was based on Lantheus’ submission referencing several publications and data supporting the safety of echocardiography contrast products in patients with cardiac shunts. Information concerning administration in patients with a cardiac shunt appears in the Warnings section of the Definity Prescribing Information.

Neil Weissman, M.D., president of MedStar Health Research Institute (Washington, D.C.), professor of medicine at Georgetown University and past president of the American Society of Echocardiography commented, “The echocardiography medical and scientific community has long demonstrated the safety of echocardiographic contrast agents through published clinical studies which has supported the removal of the contraindication for Definity in patients with cardiac shunts. This is particularly noteworthy as Definity is the most widely used echocardiography agent in the U.S. with published data supporting its safety profile across multiple care settings and across gender and race in adults, including those age 65 and older.”

Weissman continued, “This is an important step toward broader acceptance and appropriate use of echo contrast agents, which can safely and cost effectively provide critical information to help clinicians accurately diagnose and manage patients to achieve better outcomes.”

Up to 20 percent of all resting echocardiography studies and up to 30 percent of those conducted in critical care patients can result in suboptimal echocardiograms. A suboptimal image is one in which two or more contiguous left ventricular segments in any of the three apical views cannot be visualized. The use of contrast in suboptimal echocardiograms may help with clinical evaluation of the patient.

For more information: www.lantheus.com

Related Content

Bracco Diagnostics Inc. announced it will be showcasing its full portfolio of diagnostic imaging solutions in an immersive digital experience at the first all-virtual Radiological Society of North America (RSNA) annual meeting being held November 29 through December 5.
News | Contrast Media Injectors | November 17, 2020
November 17, 2020 — Bracco Diagnostics Inc.
Guerbet announced that it will highlight UNIK, a tailored solution for diagnostic imaging, at the 2020 annual meeting of the Radiological Society of North America (RSNA).
News | Contrast Media | November 17, 2020
November 17, 2020 — Guerbet announced that it will highlight UNIK, a tailored solution for diagnostic imaging, at the
Dia's LVivo artificial intelligence software can help automate many features of echocardiograms to speed workflow and aid novice users. The software is now integrated into the Konica Minolta Exa PACS. 

Dia's LVivo artificial intelligence software can help automate many features of echocardiograms to speed workflow and aid novice users. The software is now integrated into the Konica Minolta Exa PACS. 

News | Artificial Intelligence | November 12, 2020
November 12, 2020 – Konica Minolta Healthcare Americas Inc. and DiA Imaging Analysis Ltd.
An injured sonographer can be detrimental to institutions and clinics facing financial strain and lack of workforce readiness due to COVID-19.  
Sponsored Content | Case Study | Ultrasound Imaging | November 12, 2020
There is a high incidence of ultrasound work-related musculoskeletal disorders (WRMSD) among...
Enhanced axial CT (A) shows diffuse pleural thickening (arrow) with a maximum thickness of 3.17 mm. US image for the corresponding lesion on CT (B) shows diffuse pleural thickening (arrowheads) with a maximum thickness of 3.25 mm. The needle pathway length, measured as the needle length through the pleural lesion, was 6.54 mm (asterisk). Pleural puncture angle (exact value not indicated) is depicted as the angle between the outer line of the pleura and the biopsy needle (thin arrow).

Enhanced axial CT (A) shows diffuse pleural thickening (arrow) with a maximum thickness of 3.17 mm. US image for the corresponding lesion on CT (B) shows diffuse pleural thickening (arrowheads) with a maximum thickness of 3.25 mm. The needle pathway length, measured as the needle length through the pleural lesion, was 6.54 mm (asterisk). Pleural puncture angle (exact value not indicated) is depicted as the angle between the outer line of the pleura and the biopsy needle (thin arrow).

News | Ultrasound Imaging | November 09, 2020
November 9, 2020 — According to an
Honoring essential healthcareprofessionals, Nov. 8-14
News | Radiology Imaging | November 09, 2020
November 9, 2020 — As COVID-19 continues to spre
Conceptual diagram of bio-organizational crushing technology based on high-intensity concentric ultrasonography. Image courtesy of Korea Institue of Science and Technology(KIST)

Conceptual diagram of bio-organizational crushing technology based on high-intensity concentric ultrasonography. Image courtesy of Korea Institue of Science and Technology(KIST)

News | Ultrasound Imaging | November 02, 2020
November 2, 2020 — Focusing ultrasound energy on a target site in the body to generate heat can burn and destroy the
Murray Rebner, M.D., performing a breast ultrasound. Image courtesy of Beaumont Health

Murray Rebner, M.D., performing a breast ultrasound. Image courtesy of Beaumont Health

News | Breast Imaging | November 02, 2020
November 2, 2020 — Though Black women get ...